WHR1 and cancer: In contrast to the conclusions from a recently published STK19 structure study17, we provide evidence that STK19 is a monomer in solution, and demonstrate mutations found in cancer patients, K186N, R200W, and R215W, significantly compromise STK19 DNA binding, with more mutations predicted to do so.